medigraphic.com

2018, Number 3

<< Back Next >>

Cir Cir 2018; 86 (3)

Expression profile of Ki67 in palmoplantar melanocytic lesions: a case-control study

González-Ramírez RA, Barboza-Quintana O, Flores-Gutiérrez JP, de la Fuente-Villarreal D, Torres-López E, Ríos-Briones NI

Language: Spanish
References: 44
Page: 250-254
PDF size: 188.96 Kb.


ABSTRACT

Background: Acral lentiginous melanoma is a malignant neoplasm which appears in hands and feet. Acral lentiginous melanoma has an unclear etiology, and usually affects non-Caucasian population. Because it is frequently diagnosed lately, acral melanoma has bad prognosis; however, it is biologically more aggressive than other clinicopathological types of melanoma, even when diagnosed early. Objective: To determine the expression of Ki67 in invasive lentiginous acral melanoma and to compare it with acral nevi. Method: Cross-sectional, descriptive, observational study. Immunohistochemistry with Ki67 marker was performed on 17 biopsies of invasive lentiginous acral melanoma (cases) and 17 biopsies of palmoplantar nevi (controls). Nuclear expression of Ki-67 was determined and both were compared between both groups. Results: The mean expression of Ki67 was 8.5% in the control group, and 34% in the melanoma group, which was statistically significant (p ‹ 0.0001). Discussion: Ki67 expression in acral lentiginous melanomas is higher than in acral nevi. Prognostic value of Ki67 is still considered controversial. However, there are several studies where, in combination with other markers, their prognostic value is reinforced. Conclusions: Due to the wide gap in Ki67 expression between melanomas and nevi showed in this study, Ki67 expression, referred to as a proliferative index, could be considered as a prognostic factor even more objective than the mitotic index.


REFERENCES

  1. Reed RJ. Acral lentiginous melanoma. En: Hartmann W, Kay S, Reed RJ, editors. New concepts in surgical pathology of the skin. New York: Wiley; 1976. p. 89-90.

  2. Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous melanoma: a clinic-prognostic study of 126 cases. Br J Dermatol. 2006;155:561-9.

  3. Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, et al. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004;14:537-41.

  4. Hudson DA, Krige JE. Melanoma in black South Africans. J Am Coll Surg. 1995;180 65-71.

  5. Cascinelli N, Zurrida S, Galimberti V, Bartoli C, Bufalino R, Del Prato I, et al. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol. 1994;20:817-22.

  6. Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in Caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol. 2000;143:275-80.

  7. Slingluff CL Jr, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol. 1990;45:91-8.

  8. Green A, McCredie M, MacKie R, Giles G, Young P, Morton C, et al. A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control. 1999;10:21-5.

  9. Bormann G, Marsch WC, Haerting J, Helmbold P. Concomitant traumas influence prognosis in melanomas of the nail apparatus. Br J Dermatol. 2006;155:76-80.

  10. Rolón PA, Kramárová E, Rolón HI, Khlat M, Parkin DM. Plantar melanoma: a case-control study in Paraguay. Cancer Causes Control. 1997;8:850-6.

  11. O’Leary JA, Berend KR, Johnson JL, Levin LS, Seigler HF. Subungual melanoma: a review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res. 2000;(378):206-12.

  12. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in The United States, 1986- 2005. Arch Dermatol. 2009;145:427-34.

  13. Hazan C, Melzer K, Panageas AS, Li E, Kamino H, Kopf A. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer. 2002;95:634-40.

  14. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer. 1992;70:1917-27.

  15. Soong ST, Weiss HL. Predicting outcome in patients with localized melanoma. En: Balch CM, Houghton AN, Sober AJ, Soong SJ, editores. Cutaneous melanoma. 3rd ed. St. Louis: Quality Medical Publishing, Inc.; 1998. p. 51-61.

  16. Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 1993;71:3737-43.

  17. Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta- analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153:477-91.

  18. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014.

  19. Antonescu CR, Leung DH, Dudas M, Ladanyi M, Brennan M, Woodruff JM, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977-83.

  20. Hoos A, Uris MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-51.

  21. Hoos A, Stojadinovic A, Singh B. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol. 2002;160:175-83.

  22. Vishnevskaya Y, Martynkov D, Savelov N. Ki67 (MIB1) in differential diagnosis between naevi and melanomas. Eur J Cancer Supplements. 2007;5:400.

  23. Gimmoty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-56.

  24. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.

  25. Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J, Reed RJ. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol. 2003;16:525-9.

  26. Rieger E, Hoffman-Wellenhof R, Soyer HP, Kofler R, Cerroni L, Smolle J, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. J Cutan Pathol. 1993;20:229.

  27. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. P53-protein and Ki-67 antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology. 1997;30:57.

  28. Korabiowska M, Brinck U, Middel P, Brinkmann U, Berger H, Radzun HJ, et al. Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance. Anticancer Res. 2000;20:1781.

  29. Li LXL, Crotty KA, McCarthy SW, Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489.

  30. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001;195 530.

  31. Kanter-Lewensohn L, Hedblad MA, Wejde J, Larsson O. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol. 1997;10:917-20.

  32. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol. 1995;105:22-6.

  33. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res. 1999;5:2082-8.

  34. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 1998;90:1284-91.

  35. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6:1891-5.

  36. Herrera-González NE, Aco-Flores AY. El melanoma en México. Rev Esp Med Quir. 2010;15:161-4.

  37. Pozzobon F, Acosta A, Carreño A, Fierro A. Características del melanoma cutáneo primario en el Instituto Nacional de Cancerología 2006-2010. Rev Colomb Cancerol. 2013;17:111-8.

  38. Wu XC, Eide MJ, King J, Saraiya M, Huang Y, Wiggins C, et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S26-37.

  39. Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase- 2, Ki67, and p53. Hum Pathol. 2011;42:1103-11.

  40. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.

  41. Vereecken P, Laporte M, Heenen M. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review. J Cutan Pathol. 2007;34:139-45.

  42. Schimming TT, Grabellus F, Roner M, Pechlivanis S, Sucker A, Bielefeld N, et al. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol. 2012;34:266-9.

  43. Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol. 2013;26:404-13.

  44. Garbe C, Eigentler TK, Bauer J, Blödorn-Schlicht N, Cerroni L, Fend F, et al. Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. J Dtsch Dermatol Ges. 2016;14:910-5.




2020     |     www.medigraphic.com